|
- URGENT PRODUCT RECALL - bausch. com
TASS, a potential complication in any cataract surgery, is an inflammatory reaction inside the eye that can have a variety of causes When it occurs, this complication typically appears 12 – 48 hours after eye surgery - No other Bausch + Lomb products or lots distributed in the US are impacted by this recall According to our records, your facility received certain lots of Bausch + Lomb
- Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United . . .
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States | Bausch + Lomb CorporationEngineered for precision and speed, Arise uses advanced algorithms to instantly interpret corneal topography images and recommend lens designs in seconds – no fitting set required It is designed for lens fitters of all experience levels and efficiently evaluates lens centration and
- Bausch + Lomb Acquires AcuFocus, Inc. - Lomb Corporation
Bausch + Lomb Acquires AcuFocus, Inc | Bausch + Lomb CorporationAcuFocus has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eye care, including the IC-8 ® Apthera ™ intraocular lens (IOL), which was approved by the U S Food and Drug Administration in July 2022 as the first and only small aperture non-toric extended depth of focus (EDOF
- Bausch + Lomb Commercial and Manufacturing Locations
Contact information for Bausch + Lomb locations near you Any serious incidents, side effects, adverse reactions or product complaints should be reported here
- Bausch + Lomb Official Home Page
Bausch + Lomb is one of the world's largest suppliers of contact lenses, lens care products, prescription pharmaceuticals, intraocular lenses and other eye surgery products
- Investor Relations | Bausch + Lomb Corporation
We use cookies to personalise content and to analyse our traffic We also share information about your use of our site with our analytics partners View our cookies page
- Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap . . .
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences | Bausch + Lomb CorporationGlaucoma is a chronic, progressive neurodegenerative disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve As one of the leading causes of preventable blindness, glaucoma affects about four million people in the United States, but if caught early, it
- Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results . . .
Revenue of $1 280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results
|
|
|